HOME > TOP STORIES

TOP STORIES

ACADEMIA Subordinate of Former Employee of Novartis Pharma Participated in SMART Study; Protocol Violations Also Found

November 5, 2013
ACADEMIA Mismatch Found for 10% of ACR Data Between Papers, Patient Records: SMART Study

November 1, 2013
BUSINESS Takeda 1st Half Sales Rise 5.3% on New Portfolio, Weaker Yen

November 1, 2013
REGULATORY New CSIMC Healthcare Rep Nakagawa Says Against Perpetuation of Premium

October 31, 2013
ORGANIZATION PhRMA Makes Yet Another Case for Perpetuation of New Drug Premium

October 31, 2013
REGULATORY Generic Use for Anti-Allergic Agents Jumps after Pilot Leaflet Project: Kyokai Kenpo

October 30, 2013
REGULATORY 1st Committee Backs Japan Tobacco’s Hyperphosphatemia Treatment

October 30, 2013
ACADEMIA Beta Blockers “Inferior to Other Drugs,” Will Not Be Recommended as 1st–Line Treatments in New Hypertension GL

October 29, 2013
ORGANIZATION Generic Makers to Jointly Outsource GMP Inspections on Drug Substance Suppliers; Pilot to Begin by March

October 28, 2013
BUSINESS Teva’s Global Medical Director Says Biosimilars Can Cut Medical Costs

October 25, 2013
REGULATORY Regulatory Reform Council to Convene Public Discussion on Expansion of “Mixed Healthcare” on November 28

October 25, 2013
REGULATORY Diovan Panel Should Question 4 Key Figures to Dig into Scandal Further: Expert Member

October 24, 2013
REGULATORY MOF Demands Hefty Price Cuts for Long-Listed Products, Skeptical about Premium

October 23, 2013
BUSINESS Swiss Novartis Sees 22% Plunge in January-September Diovan Sales

October 23, 2013
ORGANIZATION No Clear Violation of Fair Competition Code in Diovan Case: Maker FTC Exec

October 22, 2013
BUSINESS Wholesalers’ Sluggish Price Settlement Rate Could Mar Reliability of Market Price Survey

October 22, 2013
ORGANIZATION JPMA Will Announce Response to Violation of PAL by Mitsubishi Tanabe in Near Future: Director General Goto

October 21, 2013
REGULATORY Ex-Health Minister Nagatsuma Eyes Unsworn Diet Testimony by Ex-Novartis Employee on Diovan Scandal

October 18, 2013
REGULATORY CSIMC Pricing Subcommittee OKs Indicator to Gauge Reasonableness of Premium’s Perpetuation

October 17, 2013
BUSINESS Gilead to Fully Enter Japan, File for Approval for Hepatitis C Treatment Sofosbuvir in 2014: President

October 16, 2013

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

G1 Rule to Hit Originator Biologics for First Time, Impact Seen for Up to 13 Brands

By Shinya Sato

Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…

COLUMN

The Strategic MSL: Beyond Data Delivery, It’s About Impact

By Philip Carrigan

I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…